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   ABSTRACT 
 
Background: Beta-glucan has been frequently 
used in laboratory trials as an immunomodulator 
in both in vivo and in vitro studies, but the ef-
fective dose for measuring its performance has 
not been established. Like other immunomodula-
tors, researchers must establish the right dose of 
beta-glucan in their laboratory experiments for 
the purpose of testing substances as immuno-
modulators without achieving false-positive or –
negative results. This study aimed to determine 
the optimum dose of beta-glucan to induce cyto-
kine production by peripheral blood mononu-
clear cells (PBMCs) in vitro. 
Subjects and Method: This was a laboratory 
experimental study. This study measured the 
production of two cytokines, including interferon 
gamma (IFN-γ) and interleukin 12 (IL-12), from 
the isolated PBMCs of healthy subjects. The doses 
of beta-glucan used as immunomodulator inclu-
ded 1, 5, 10, 20, and 50 μg/ml. Beta-glucan was 
added to the PBMC culture medium, and the 
PBMCs were cultured for 6 days. On the sixth 
day, the supernatant was harvested and the 
cytokine production was analyzed using sandwich 
enzyme-linked immunosorbent assay (ELISA). 
Cytokines were also analyzed using the human 
IFN-γ ELISA kit and the human IL-12 ELISA kit, 
and data analysis was performed by one-way 
ANOVA.  
Results: IFN-γ levels were found to be increased 
in the group treated with 5 μg/ml beta-glucan. 
The highest IFN-γ levels (70.0 pg/ml) were 
observed in the group treated with 10 μg/ml beta-
glucan. The production of IL-12 increased sharply 
in the group treated with5 μg/ml beta-glucan but 
decreased in the group treated with 10 μg/ml 
beta-glucan. The mean cytokine levels of the 
beta-glucan group were found to be significantly 
different from those of the control group 
(p=0.001). One-way ANOVA revealed that the 
highest IL-12 production (77.2 pg/ml) occurred 
at a dose of 5 μg/ml beta-glucan. This average 
value was significantly different from the average 
production of IL-12 in the control group 
(p=0.001). 
Conclusion: The optimum dose of beta-glucan 
for stimulating PBMCs to produce IFN-γ in vitro 
was 10 μg/ml, while for the production of IL-12, 
the dose was 5 μg/ml. Both cytokines can be mea-
sured within 6 days of cell culture. 
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BACKGROUND 
Cytokines are protein molecules secreted by 
cells and are involved in intercellular com-
munication, acting as mediators to enhance 
the immune response through interaction 
with specific cell surface receptors in leuko-
cytes (Peters, 1996). Immune cells must pro-
duce enough cytokines to keep the body heal-
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thy in cases of both the invasion of pathoge-
nic microorganisms and the occurrence of 
cell malignancy processes. The occurrence of 
genetic defects causes less cytokine produc-
tion, due to which the body becomes suscep-
tible to disease (Ramirez-Alejo and Santos-
Argumedo, 2014; Bustamantea et al., 2014; 
Caragol and Casanova, 2003). The primary 
cytokines that play an important role in 
fighting bacterial infections are interferon 
gamma (IFN-γ) and interleukin 12 (IL-12) 
(Lauw, 2000). IL-12 is a regulatory cytokine 
that activates natural killer (NK) cells and T 
helper 1 (Th1) cells to produce IFN-γ (Budak 
et al., 2008). Meanwhile, IFN-γ itself plays 
an important role in activating the process of 
phagocytosis and improves protection 
against intracellular bacterial infections by 
increasing proactive reactive oxygen species 
(ROS) (Marchi et al., 2014). 
Various substances are known to act as 
immunomodulators that can stimulate cyto-
kine production. One of the substances used 
as an immunomodulator is beta-glucan. Util-
ization of beta-glucan as an immunomodu-
lator developed along with the progress in the 
concept of complementary alternative medi-
cine or modalities (CAM), which began to 
develop again in the early 2000s. The re-
search on medicinal mushrooms as a comple-
mentary therapy has been widely increasing 
along with the development of CAM appli-
cation in the society (Shah et al., 2011). Beta-
glucan can be extracted from various living 
things such as yeast, mushroom, barley, and 
wheat, (Noss et al., 2013; Limberger-Bayer et 
al., 2014; Goncalves et al., 2014) and it has 
become one of the substances that has been 
intensively studied as an immunomodulator 
in various diseases caused by malignancy or 
infection processes (Yun et al., 2003; Chan et 
al., 2009). 
Beta-glucan has been used in laboratory 
experiments as an immunomodulator in both 
in vivo and in vitro studies (Javmen et al., 
2015, but the effective dose has not yet been 
determined to measure its performance. 
Researchers have used different doses of 
beta-glucan in their experiments. Like other 
immunomodulators, it is necessary to esta-
blish an appropriate dose for use in labora-
tory experiments, so that the research object-
ives can be achieved without positive-false or 
-negative results.  
Therefore, the aims of this study were 
to determine the optimum dose of beta-glu-
can to induce cytokine production by peri-
pheral blood mononuclear cells (PBMCs) in 
vitro and to provide basic research data and a 
scientific basis for its application in labora-
tory assessment. 
 
SUBJECTS AND METHOD 
1. Study Design 
This was a laboratory experimental study 
that compared the effects occurring in the 
treatment group and the control group. 
2. Population and Sample 
In this study, PBMCs isolated from healthy 
donors were used as the research subject. The 
inclusion criteria of the subjects were as fol-
lows: healthy men or women aged 18–25 
years, showing negative test results for HIV, 
hepatitis B, and hepatitis C screening (con-
ducted at RSU Banyumanik Semarang), and 
not taking immunosuppressant or immuno-
modulators. Before participation in the study, 
the subjects were briefed about the study and 
agreed to be involved in the research by 
signing the informed consent form. 
3. Study Variables 
The dependent variable was cytokines pro-
duction. The independent variable were 
doses of beta-glucan for Stimulating PBMCs. 
4. Operational Definition of Variables 
Isolation and Culture of PBMCs were 
carried out according to the following steps. 
A total of 4 ml of peripheral blood of subjects 
was collected into a heparin lithium tube 
(Endo Vacu Tube) and allowed to stand for 
Erawati et al./The optimum dose of beta-glucan for stimulating peripheral blood mononuclear cells 
www.theijmed.com  172 
60 min at room temperature. The tube was 
then centrifuged at 1500 rpm for 15 min. 
Then, Ficoll (Amersham Ficoll-Paque PLUS) 
was added to the tube and centrifuged at 
1500 rpm for 15 min. The buffy coat was col-
lected and washed twice with PBS. In the 
PBMC tube, 1 ml of complete RPMI medium 
was added, and the cells were counted under 
a microscope using a hemocytometer. PBM-
Cs(5 × 105/ml) were cultured in 24-well pla-
tes containing the complete RPMI medium as 
the control group and in plates containing the 
RPMI medium added with beta-glucan at 
various doses, including 1, 5, 10, 20, and 50 
μg/ml, as the treatment groups. Subsequent-
ly, the cells were incubated in a 5% CO2 incu-
bator at 37°C for 6 days. 
Beta-Glucanof manufactured baker’s yeast 
Saccharomyces cerevisiae was used. Before 
use, beta-glucan was dissolved in ultrapure 
water and vortexed for 15 min. 
Measurement of Cytokines (IFN-γ and 
IL-12) were assessed in this study. On the 
sixth day, the supernatant was collected and 
the cytokine production was determined 
using sandwich enzyme-linked immunosor-
bent assay (ELISA). The cytokines were fur-
ther analyzed using the human IFN-γ ELISA 
kit and the human IL-12 ELISA kit according 
to the manufacturer’s instructions. The col-
lected supernatant was centrifuged at 1000 
rpm for 20 min. Before use, the plate was 
rinsed twice. The standard and a sample of 
100 μl were collected into each well and 
incubated at 37°C for 90 min. Furthermore, 
100 μl of biotin-detection antibody working 
solution was added to each well and incuba-
ted at 37°C for 60 min. The plate was washed 
three times. Into each well of the plate, 100 μl 
of SABC working solution was added and in-
cubated at 37°C for 30 min. The washing step 
was performed five times. Then, 90 μl of 
TMB substrate was added and incubated for 
15 min at 37°C. In the next step, 50 μl of stop 
solution was added, and the cytokine levels 
were read on a micro plate reader at an 
optical density (OD) of 450 nm absorbance. 
5. Data Analysis 
The normality of data was assessed using the 
Kolmogorov–Smirnov test, while the compa-
rison between treatments was done using 
one-way ANOVA. Data were displayed and 
analyzed using Microsoft Excel 2010 and 
IBM SPSS Statistics 20, with the significance 
level set at p <0.05. 
6. Research Ethic 
This study was conducted with the approval 
of the Committee on Ethical Research for 
Health of the Faculty of Medicine, Dipone-
goro University, and the Kariadi Hospital, Se-
marang, Indonesia. Ethical clearance for this 
project is available under the registration no. 
467/EC/FK-RSDK/VII/2017 at the secreta-
riat of the Committee on Ethical Research for 
Health of the Faculty of Medicine, Diponego-
ro University, and the Kariadi Hospital. La-
boratory tests were conducted at the Para-
sitology Laboratory of the Faculty of Me-
dicine, Gadjah Mada University, Yogyakarta, 
from March to April 2018. 
 
RESULTS 
The production of IFN-γ and IL-12 was 
measured in the six PBMC groups, including 
the control group and the groups treated with 
1, 5, 10, 20, and 50 μg/ml of beta-glucan. 
Figure 1 shows the results of IFN-γ and IL-12 
measurements for the treatment and the 
control groups. IFN-γ levels were increased 
in the PBMC group cultured with the addi-
tion of beta-glucan from the dose of 5 μg/ml 
till the dose of 10 μg/ml, at which the highest 
IFN-γ level was detected. In addition, at the 
subsequent dose (20 μg/ml), the IFN-γ level 
began to decrease. The PBMC group treated 
with 50 μg/ml beta-glucan also showed a de-
crease in IFN-γ level. 
 
Erawati et al./ The optimum dose of beta-glucan for stimulating peripheral blood mononuclear cells 
 
www.theijmed.com  173 
 
Figure 1. Cytokine production by PBMCs in control group  
and treatment groups 
 
Meanwhile, the highest level of IL-12 
production was detected in the group treated 
with5 μg/ml beta-glucan. In the PBMC 
cultures treated with 10 µg/ml beta-glucan, 
the IL-12 production was decreased, but at 
the dose of 20 µg/ml beta-glucan, the IL-12 
levels started to elevate. However, at the dose 
of 50 µg/ml, the levels of IL-12 decreased 
again.To determine the optimum dose of 
beta-glucan to be used as an immunomodula-
tor, the normality was assessed using the Kol-
mogorov–Smirnov test, which showed that 
both IFN-γ and IL-12 data were normally 
distributed. Furthermore, one-way ANOVA 
was conducted to determine the difference in 
the mean production of both cytokines under 
various treatments. The results of both tests 
are presented in Table 1. 
Table 1. The mean distribution of IFN-γ and IL-12 data according to the dose of beta-
glucan 
Variable Dose of beta-glucan (µg/ml) Mean (pg/ml) SD p 
IFN-γ 0 43.7 0.35 0.001 
 1 32.0 4.24  
 5 47.0 5.65  
 10 70.0 1.41  
 20 65.2 1.76  
 50 35.2 1.06  
IL-12 0 57.0 2.28 0.001 
 1 54.0 1.41  
 5 77.2 1.76  
 10 53.0 2.12  
 20 65.0 1.41  
 50 51.7 2.47  
 
The ANOVA showed that the highest 
IL-12 production (77.2 pg/ml) occurred at the 
dose of 5 μg/ml beta-glucan. This average 
value was significantly different from the 
mean value of IL-12 production in the control 
group (p= 0.001). 
 
DISCUSSION 
The concept of CAM describes that biologi-
cally based therapies use typically natural 
substances and include herbs and essential 
oils, special diets, nutritional and food supple-
ments, and other products (Kramlich, 2014) 
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concept, the results of this study show that 
the beta-glucan extracted from the yeast S. 
cerevisiae can be used as an immunemodu-
lator, particularly acting as a stimulator of 
IFN-γ and IL-12 production in vitro. There 
are various types of glucan molecules that 
can be extracted from various sources, in-
cluding mushrooms, yeast, wheat, and other 
plants. The potential of glucan as an immu-
nomodulator is determined by its structure 
and molecular weight (Choromanska et al., 
2018).In this study, the beta glucan used as 
immunomodulator was derived from S. cere-
visiae because of the structure of β- (1,3) - 
(1,6) -glucan and molecular weight (35–5000 
kDa), this glucan indicates its potential to be 
used as an immunomodulator, particularly to 
induce the production of cytokines by immu-
ne cells (Noss et al., 2013). 
Certain substances can affect the phy-
siology of the body at the right dosage. Ad-
ministering substances in quantities that are 
too small cannot produce the expected effect, 
but administering excessive quantity will also 
have an impact on the occurrence of toxicity 
to targeted cells or organs. To obtain the right 
dose according to the expected goals, resear-
chers must test various doses repeatedly, es-
pecially for new substances that are not yet 
widely known. Several previous studies have 
shown that the potential of beta-glucan as an 
immunomodulator depends on the given 
dose. Some of the cytokines that can be sti-
mulated by beta-glucan include IFN-γ, IL-12 
(Budak, 2008), TNF-α, IL-6, and IL-8 (Noss 
et al., 2013). 
In this study, compared with the con-
trol group and other beta-glucan doses, the 
highest production of IFN-γ was observed in 
PBMCs treated with 10 μg/ml beta-glucan for 
6 days, whereas the highest production of IL-
12 was detected in PBMCs treated with 5 
μg/ml beta-glucan for 6 days. These results 
are slightly different from those of previous 
studies using a single dose of 5 μg/ml beta-
glucan to obtain the immunomodulator ef-
fects of PBMCs on both IFN-γ and IL-12 pro-
duction (Budak et al., 2008). 
 Beta-glucan is administered at differ-
rent doses and times according to the desired 
goal. In rats infected with influenza virus, 
beta-glucan may reduce the risk of death 
from infection at a dose of 881.5 μg/day for 
12 days by preventing massive weight loss, 
stimulating the ability of phagocytosis by 
mouse peripheral blood neutrophils, and 
killing by NK cells, as well as by increasing 
the production of several cytokines such as 
IFN-γ, IL-1β, and TNF-α (Vitvicka et al., 
2015). Other experiments were performed on 
mice with polymicrobial infection. After 1 h of 
infection, mice were administered 10 mg/kg 
of body weight of PGG glucan. After 6 h, the 
cytokines were measured in blood samples. 
Results showed that the PGG glucan enhan-
ced the survival in female mice over a 10-day 
period, but survival in males was improved 
for only 24 h. In female mice, PGG glucan 
reduced the levels of IL-6 and IL-10 and also 
reduced the bacterial burden in the liver 
(Newsome et al., 2011).  
In addition to its use to boost the im-
mune host system during infection, beta-glu-
can is often used to enhance the immune sys-
tem in malignancy. Beta-glucan extracted 
from S. cerevisiae has growth inhibitory ef-
fects against the murine mammary adenocar-
cinoma AMN-3 cell line depending on time 
and concentration. The highest effect was 
obtained with the beta-glucan extract at 
higher concentrations after 48 h of exposure 
in the AMN-3 cell line (Jabber et al., 2011).  
In patients with prostate cancer who 
were administered 20mg of soluble beta-
glucan in the form of a carboxymethylated 
(CM-G) capsule daily for 28 days, the total 
leukocyte count increased significantly (p= 
0.02), with no associated changes in the life-
style habits of the patients. A significant 
increase (p=0.001) was also observed in red 
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blood cell, hematocrit, hemoglobin, and pla-
telet counts. No changes were observed in the 
hepatic or renal function after CM-G admi-
nistration, and there were also no side effects 
associated with its use (Magnani et al., 2010).  
In addition to improving the fitness of 
immune cells so that they can function opti-
mally, one of the mechanisms of beta-glucan 
to help the body fight against malignancy is 
by activating immune responses to induce 
cell apoptosis through the caspase-3-depen-
dent signaling pathway and to inhibit cell 
proliferation possibly via the p53-dependent 
signaling pathway in vivo. Besides, it has 
been reported that LNT inhibited angioge-
nesis by suppressing VEGF expression, lead-
ing to slow progression of tumors (Xu et al., 
2016). 
This study demonstrated that the global 
cytokine production in the beta-glucan group 
was increased significantly (p<0.05). The 
optimum dose of beta-glucan for stimulating 
PBMCs to produce IFN-γ in vitro was 10 
μg/ml, while it was 5 μg/ml to induce the 
production of IL-12 by PBMCs. Both cyto-
kines can be measured on the sixth day of cell 
culture. These findings suggest that beta-glu-
can is useful as a complementary or adjuvant 
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